Edition:
United States

Nabriva Therapeutics PLC (NBRV.OQ)

NBRV.OQ on NASDAQ Stock Exchange Global Select Market

2.53USD
21 Sep 2018
Change (% chg)

$-0.01 (-0.39%)
Prev Close
$2.54
Open
$2.57
Day's High
$2.57
Day's Low
$2.53
Volume
72,593
Avg. Vol
117,589
52-wk High
$8.56
52-wk Low
$2.34

Select another date:

Mon, May 21 2018

Nabriva shares tumble as safety worries plague pneumonia drug

Nabriva Therapeutics Plc's antibiotic drug to treat a common form of pneumonia met the main goal of a key clinical trial, but concerns over its side effects sent the drug developer's shares down 13 percent on Monday.

UPDATE 3-Nabriva shares tumble as safety worries plague pneumonia drug

* Co to seek approval for drug in Q4 2018 (Adds analyst quote, updates stock price)

BRIEF-Nabriva Announces Positive Results For Pneumonia Treatment

* NABRIVA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF ORAL LEFAMULIN FOR THE TREATMENT OF COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA

Nabriva's pneumonia drug succeeds in late-stage study

May 21 Nabriva Therapeutics Plc said on Monday its drug to treat adults suffering from a type of pneumonia met the main goal of a late-stage study.

BRIEF-Nabriva Therapeutics Reports Q1 Loss Per Share $0.36

* NABRIVA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

BRIEF-Nabriva Therapeutics And Roivant Sciences Enter Into License Agreement

* NABRIVA THERAPEUTICS AND ROIVANT SCIENCES ENTER INTO LICENSE AGREEMENT TO DEVELOP AND COMMERCIALIZE LEFAMULIN IN GREATER CHINA

Select another date: